EGFR and non-small cell lung carcinoma: Since the first TKIs were introduced, researchers have focused on some hot terms such as NSCLC, EGFR, CML, EGFR-TKI, EGFR mutation, erlotinib, imatinib, osimertinib, gefitinib, targeted therapy, renal cell carcinoma, resistance.